Vista OS, Vista AI Scan, RTHawk
K251029Vista AI, Inc. · cleared 2025-08-21 · product code LNH · Radiology
Premarket evidence — what FDA accepted
source quote (p.6)
“RTHawk is a software platform designed from the ground up to provide efficient MRI data acquisition, data transfer, image reconstruction, and interactive scan control and display of static and dynamic MR imaging data. The AI algorithms within the Vista OS system are designed to assist MRI technologists which are always in control of the scan process. The software automates aspects of MRI setup and parameter selection to help reduce exam time, simplify the workflow, and increase reliability.”
source quote (p.8)
“The system uses neural networks for image analysis, with no generative AI employed. These models have a multi-layered architecture that reduces data to the most relevant set for inline image analysis.”
source quote (p.8)
“The system uses neural networks for image analysis, with no generative AI employed.”
Validation studies (6)
Retrospective clinical
n=120 images
endpoints: 80% agreement between neural-network assessment at its default sensitivity level and the cardiologist reader
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Retrospective clinical
n=100 other
endpoints: 80% agreement between neural-network assessment at its default sensitivity level and the cardiologist reader
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Retrospective clinical
n=209 images
endpoints: denoising should not detract from diagnostic accuracy in all cases; diagnostic quality of the denoised data be judged superior to its paired non-denoised series in more than 80% of test cases
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Retrospective clinical
n=323 images
endpoints: mean error in plane angulation of less than 3 degrees with standard deviation less than 5 degrees; mean plane position error less than 5 mm with standard deviation less than 15 mm
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Retrospective clinical
n=329 images
endpoints: mean 3D Intersection-over-Union (IoU) metrics of at least 0.65 for each volumetric scan prescription
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Retrospective clinical
n=42 other
endpoints: average velocity error should be less than 10% individually for all vessels and views
standards: IEC 60601-2-33:2022-08 (Ed. 4.0), IEC 60601-1:2020 (Ed. 3.2), MS1-2008, MS3-2008, MS4-2010, MS8-2016, NEMA PS3.1 - 3.20 (2023e), ISO 14971:2019
Reported performance (2 observations)
source quote (p.10)
“The primary acceptance criterion for this test was 80% agreement between neural-network assessment at its default sensitivity level and the cardiologist reader.”
source quote (p.10)
“The primary acceptance criterion for this test was 80% agreement between neural-network assessment at its default sensitivity level and the cardiologist reader.”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- recall_reason_pattern
Software/algorithm-related recall in product code LNH (Philips North America, initiated 2026-04-14): "The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction " Recalling firm is another firm in the same product code.
first seen 2026-07-08 · recall res_event_number:98779
- recall_reason_pattern
Software/algorithm-related recall in product code LNH (Philips North America, initiated 2025-12-03): "The potential for stiffness value errors when viewing exported MR Elastography (MRE) stiffness maps to viewer Picture Archiving and Communication System (PACS)." Recalling firm is another firm in the same product code.
first seen 2026-07-08 · recall res_event_number:98111
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device); a recall is shown as device-attributed only when the recall record itself lists this clearance number. Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).
Applicable FDA guidance — what the submission is measured against
FDA guidance documents and guiding principles applicable to 510(k) AI/ML devices in the Radiology panel. A curated reference index, not legal or regulatory advice — each item states its own status, and a draft is never binding.
- Final guidanceRadiology-specific2022-09Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions
Radiology CADe/CADx · Software premarket content
Original July 2012; current database date reflects a Sept 2022 reissue. Governs CADe device 510(k) content.
- Final guidanceRadiology-specific2022-09Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions
Radiology CADe/CADx
Original July 2012, revised 2020; current database date Sept 2022. Covers standalone and reader-study performance assessment for CADe.
- Final guidanceRadiology-specific2022-06Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions
Quantitative imaging · Radiology CADe/CADx
Final (June 2022). Relevant to devices outputting quantitative imaging measurements.
- Final guidance2026-01Clinical Decision Support Software
Clinical decision support · SaMD (general)
New final guidance issued Jan 2026, superseding the Sept 2022 version; narrows the device-CDS scope. Applies to software that informs clinical management.
- Final guidance2026-01General Wellness: Policy for Low Risk Devices
SaMD (general) · Clinical decision support
Revised final (Jan 2026); now addresses noninvasive products estimating physiologic parameters (SpO2, BP, glucose). Reshapes the device / non-device line for AI wellness features.
- Final guidance2025-09Computer Software Assurance for Production and Quality Management System Software
SaMD (general) · Postmarket
Final (Sept 2025). Covers software used in production/QMS (incl. ML development-pipeline tooling), superseding Section 6 of the 2002 GPSV — not device software functions themselves.
- Final guidance2025-06Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
Cybersecurity · Software premarket content
Reissued June 2025 (retitled 'Quality Management System', was Sept 2023 'Quality System'); adds coverage of FD&C Act §524B cyber devices.
- Final guidance2024-12Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
Predetermined Change Control Plan · AI/ML lifecycle · Software premarket content
Final (Dec 2024). Supersedes the April 2023 AI/ML PCCP draft.
- Final guidance2023-10Electronic Submission Template for Medical Device 510(k) Submissions
Software premarket content
eSTAR has been mandatory for 510(k)s since Oct 2023 — operationally unavoidable, though not AI-specific.
- Final guidance2023-08Off-The-Shelf Software Use in Medical Devices
Software premarket content · SaMD (general)
Final (Aug 2023). Applies when a device incorporates off-the-shelf software components (common in ML stacks).
- Final guidance2023-06Content of Premarket Submissions for Device Software Functions
Software premarket content · SaMD (general)
Final (June 2023); replaced the May 2005 'Software Contained in Medical Devices' guidance. Documentation level drives the software content of the submission.
- Final guidance2022-09Policy for Device Software Functions and Mobile Medical Applications
SaMD (general) · Clinical decision support
Current version Sept 2022. Frames which software functions FDA regulates as devices.
- Final guidance2021-10De Novo Classification Process (Evaluation of Automatic Class III Designation)
De Novo pathway
Final (Oct 2021), issued with the De Novo final rule. Most relevant to first-of-a-kind devices without a predicate (DEN-numbered clearances).
- Final guidance2016-12Postmarket Management of Cybersecurity in Medical Devices
Cybersecurity · Postmarket
- Final guidance2002-01General Principles of Software Validation
SaMD (general) · Software premarket content
Still active except Section 6 (superseded Sept 2025 by the Computer Software Assurance final guidance).
- Draft guidance2025-01Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations
AI/ML lifecycle · Software premarket content · Transparency
Draft as of July 2026 (published Jan 2025); finalization is on CDRH's FY2026 agenda but not yet published. Treat as FDA's stated direction, not a binding expectation.
- Draft guidance2024-08Predetermined Change Control Plans for Medical Devices
Predetermined Change Control Plan · Postmarket
Draft (Aug 2024) extending PCCPs beyond AI to all devices under FD&C §515C; not final as of July 2026.
- Guiding principles2024-06Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
Transparency · AI/ML lifecycle
- Guiding principles2023-10Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles
Predetermined Change Control Plan · AI/ML lifecycle
FDA/Health Canada/MHRA joint principles (Oct 2023); companion to the GMLP and Transparency principles.
- Guiding principles2021-10Good Machine Learning Practice for Medical Device Development: Guiding Principles
AI/ML lifecycle · SaMD (general)
FDA/Health Canada/MHRA joint principles (Oct 2021). Foundational, not a binding guidance; IMDRF issued a related GMLP document Jan 2025.
Applicability is derived from the device's FDA advisory panel and pathway — cross-cutting guidances apply to every AI/ML device; panel-specific ones are flagged. Titles, dates, and links verified against fda.gov as of July 2026.